Re the prior post... There's a difference between high risk and "no real opportunity". This is indeed a high risk investment, and it is not for money that one cannot afford to lose. But there is certainly a real opportunity for significant success here. If I remember correctly, an analyst (i.e., not a cheerleader) set a price target of $2-$5 last year. If that happens, I'd say that the folks who got in under a quarter have quite an opportunity indeed. And that is assuming no real movement in domestic, FDA-regulated markets. With mainstream pharma (e.g., Novartis) now taking a look at MSC technologies, that might not be the case for long. More than anything, and despite all the bashing that went on last year, VB is a reputable company with real technology and responsive management -- unlike the majority of small companies in the stem cell space. This matters a lot. Irresponsible stem cell companies come and go. But VB has hung in there, because it has been committed to pursuing a well-conceived R&D path steadily, without blowing through limited capital like a drunken sailor.
